Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b 002F2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California. The company trades on NASDAQ exchange. The company headquarter is located in South San Francisco, CA. The company was established in the 2015.

TickerKZR
Long NameKezar Life Sciences, Inc.
Short NameKezar Life Sciences